Semin Neurol 2012; 32(03): 215-226
DOI: 10.1055/s-0032-1329200
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Myasthenia Gravis

Nicholas J. Silvestri
1   Department of Neurology, State University of New York at Buffalo, Buffalo General Medical Center, Buffalo, New York
,
Gil I. Wolfe
1   Department of Neurology, State University of New York at Buffalo, Buffalo General Medical Center, Buffalo, New York
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
01. November 2012 (online)

Abstract

Myasthenia gravis (MG) is the most common disorder of the neuromuscular junction (NMJ), with an estimated prevalence between 25 and 142 per million. It characteristically presents with fatigable weakness, often initially involving the ocular muscles and manifesting as intermittent ptosis and diplopia. Ultimately, the disease generalizes in two-thirds of patients, leading to weakness of bulbar, neck, limb, and respiratory muscles. The majority of patients with generalized MG, and roughly half of patients with purely ocular disease, harbor antibodies to skeletal muscle nicotinic acetylcholine receptors. A subset of patients with generalized disease have antibodies to muscle-specific receptor tyrosine kinase (MuSK). Acetylcholinesterase inhibitors are often the first modality of therapy for MG. As an immune-mediated disorder, MG can respond to several immunosuppressive agents, such as corticosteroids, azathioprine, mycophenolate mofetil, and cyclosporin. Thymectomy is a key component of management in appropriately chosen MG patients and those with thymoma. Newer or alternative immunotherapies including tacrolimus, rituximab, methotrexate, and complement inhibiting agents are an area of active investigation.

 
  • References

  • 1 McGrogan A, Sneddon S, de Vries CS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology 2010; 34 (3) 171-183
  • 2 Simpson J. Myasthenia gravis: a new hypothesis. Scott Med J 1960; 5: 419-436
  • 3 Lindstrom JM, Lennon VA, Seybold ME, Whittingham S. Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci 1976; 274: 254-274
  • 4 Vincent A, Drachman DB. Myasthenia gravis. In: Pourmand R, Harati Y, , eds. Advances in Neurology: Neuromuscular Disorders. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 159-188
  • 5 Kaminski HJ. Myasthenia gravis. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, , eds. Neuromuscular Disorders in Clinical Practice. Boston, MA: Butterworth-Heinemann; 2002: 916-930
  • 6 Kawaguchi N, Kuwabara S, Nemoto Y , et al; Study Group for Myasthenia Gravis in Japan. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci 2004; 224 (1–2) 43-47
  • 7 Kleinwächter. Beobachtung über die wirkung des calabar-extracts gegen atropin-vergiftung. Berl Klin Wochensch 1864; 38: 369-371
  • 8 Laqueur L. Ueber atropin und physostigmin und ihre wirkung auf den intraocularen druck. Ein beitrag zur therapie des glaucoms. Graefes Arch Clin Exp Ophthalmol 1877; 23: 149-176
  • 9 Walker MB. Treatment of myasthenia with physostigmine. Lancet 1934; 1: 1200-1201
  • 10 Wolfe GI, Barohn RJ, Galetta SL. Drugs for the diagnosis and treatment of myasthenia gravis. In: Zimmerman T, Kooner K, Sharir M, Fechtner RD, , eds. Textbook of Ocular Pharmacology. Philadelphia, PA: Lippincott-Raven Press; 1997: 837-848
  • 11 Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330 (25) 1797-1810
  • 12 Reynolds J , Ed. Martindale: The Extra Pharmacopoeia. 30th ed. London, UK: The Pharmaceutical Press; 1993
  • 13 Sanders DB, Scoppetta C. The treatment of patients with myasthenia gravis. Neurol Clin 1994; 12 (2) 343-368
  • 14 Sommer N, Sigg B, Melms A , et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62 (2) 156-162
  • 15 Hatanaka Y, Hemmi S, Morgan MB , et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology 2005; 65 (9) 1508-1509
  • 16 Pasnoor M, Wolfe GI, Nations S , et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010; 41 (3) 370-374
  • 17 Blalock A, Mason MF, Morgan HJ, Riven SS. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. Ann Surg 1939; 110 (4) 544-561
  • 18 Blalock A, Harvey AM, Ford FR, Lilienthal JL. The treatment of myasthenia gravis by removal of the thymus gland. JAMA 1941; 117: 1529-1533
  • 19 Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990; 40 (12) 1828-1829
  • 20 McQuillen MP, Leone MG. A treatment carol: thymectomy revisited. Neurology 1977; 27 (12) 1103-1106
  • 21 Gronseth GS, Barohn RJ. Thymectomy for non-thymomatous autoimmune myasthenia gravis (an evidence-based review). Neurology 2000; 55: 7-15
  • 22 Jaretzki A, Barohn RJ, Ernstoff RM. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55: 16-23
  • 23 Wolfe GI, Kaminski HJ, Jaretzki III A, Swan A, Newsom-Davis J. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci 2003; 998: 473-480
  • 24 Lee CY, Kim DJ, Lee JG , et al. Bilateral video-assisted thorascopic thymectomy has a surgical extent similar to that of extended transsternal thymectomy with more favorable early surgical outcomes for myasthenia gravis patients. Surg Endosc 2011; 25: 849-854
  • 25 Zahid I, Sharif S, Routledge T, Scarci M. Video-assisted thoracoscopic surgery or transsternal thymectomy in the treatment of myasthenia gravis?. Interact Cardiovasc Thorac Surg 2011; 12 (1) 40-46
  • 26 Freeman RK, Ascioti AJ, Van Woerkom JM, Vyverberg A, Robison RJ. Long-term follow-up after robotic thymectomy for nonthymomatous myasthenia gravis. Ann Thorac Surg 2011; 92 (3) 1018-1022 , discussion 1022–1023
  • 27 Weksler B, Tavares J, Newhook TE, Greenleaf CE, Diehl JT. Robot-assisted thymectomy is superior to transsternal thymectomy. Surg Endosc 2012; 26 (1) 261-266
  • 28 Jaretzki III A. Thymectomy for myasthenia gravis: analysis of the controversies regarding technique and results. Neurology 1997; 48 (Suppl. 05) S52-S63
  • 29 Jaretzki III A, Wolff M. “Maximal” thymectomy for myasthenia gravis. Surgical anatomy and operative technique. J Thorac Cardiovasc Surg 1988; 96 (5) 711-716
  • 30 Jaretzki III A, Aarli JA, Kaminski HJ, Phillips II LH, Sanders DB. Medical/Scientific Advisory Board, Myasthenia Gravis Foundation of America, Inc.. Thymectomy for myasthenia gravis: evaluation requires controlled prospective studies. Ann Thorac Surg 2003; 76 (1) 1-3
  • 31 Mantegazza R, Baggi F, Bernasconi P , et al. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci 2003; 212 (1–2) 31-36
  • 32 Takanami I, Abiko T, Koizumi S. Therapeutic outcomes in thymectomied patients with myasthenia gravis. Ann Thorac Cardiovasc Surg 2009; 15 (6) 373-377
  • 33 Liu Z, Feng H, Yeung SCJ , et al. Extended transsternal thymectomy for the treatment of ocular myasthenia gravis. Ann Thorac Surg 2011; 92 (6) 1993-1999
  • 34 Rodriguez M, Gomez MR, Howard Jr FM, Taylor WF. Myasthenia gravis in children: long-term follow-up. Ann Neurol 1983; 13 (5) 504-510
  • 35 Adams C, Theodorescu D, Murphy EG, Shandling B. Thymectomy in juvenile myasthenia gravis. J Child Neurol 1990; 5 (3) 215-218
  • 36 Lakhoo K, De Fonseca J, Rodda J, Davies MRQ. Thymectomy in black children with juvenile myasthenia gravis. Pediatr Surg Int 1997; 12: 113-115
  • 37 Johns TR. Long-term corticosteroid treatment of myasthenia gravis. Ann N Y Acad Sci 1987; 505: 568-583
  • 38 Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15 (3) 291-298
  • 39 Richman DP, Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann N Y Acad Sci 2003; 998: 457-472
  • 40 Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med 1972; 286 (1) 17-20
  • 41 Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 2008; 71 (17) 1335-1341
  • 42 Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60 (2) 243-248
  • 43 Benatar M, Kaminski HJ. Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2007; 68 (24) 2144-2149
  • 44 Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974; 290 (2) 81-84
  • 45 Wolfe GI, Barohn RJ. Neuromuscular junction disorders of childhood. In: Swaiman KF, Ashwal S, Ferriero DM, , eds. Pediatric Neurology: Principles and Practice. 4th ed. Philadelphia, PA: Mosby Elsevier; 2006: 1941-1968
  • 46 Massey JM. Treatment of acquired myasthenia gravis. Neurology 1997; 48 (Suppl. 05) S46-S51
  • 47 Miano MA, Bosley TM, Heiman-Patterson TD , et al. Factors influencing outcome of prednisone dose reduction in myasthenia gravis. Neurology 1991; 41 (6) 919-921
  • 48 Grossman JM, Gordon R, Ranganath VK , et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62 (11) 1515-1526
  • 49 Rivner MH. Steroid treatments for myasthenia gravis: steroids are overutilized. Muscle Nerve 2002; 25: 115-117
  • 50 Bedlack RS, Sanders DB. Steroid treatment for myasthenia gravis: steroids have an important role. Muscle Nerve 2002; 25 (1) 117-121
  • 51 Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235 (8) 449-453
  • 52 Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984; 15 (6) 602-605
  • 53 Palace J, Newsom-Davis J, Lecky B. Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50 (6) 1778-1783
  • 54 Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci 1981; 377: 691-699
  • 55 Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56 (1) 94-96
  • 56 Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 2001; 56 (1) 97-99
  • 57 Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 2005; 65 (4) 639-641
  • 58 Dubal DB, Mueller S, Ruben BS, Engstrom JW, Josephson SA. T-cell lymphoproliferative disorder following mycophenolate treatment for myasthenia gravis. Muscle Nerve 2009; 39 (6) 849-850
  • 59 Meriggioli MN, Ciafaloni E, Al-Hayk KA , et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003; 61 (10) 1438-1440
  • 60 Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71 (6) 394-399
  • 61 Sanders DB, Hart IK, Mantegazza R , et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71 (6) 400-406
  • 62 Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41 (5) 593-598
  • 63 Tindall RSA, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 539-551
  • 64 Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987; 316 (12) 719-724
  • 65 Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 2000; 55 (3) 448-450
  • 66 Schalke B, Kappos L, Dommasch D , et al. Cyclosporin A treatment of myasthenia gravis: initial results of a double-blind trial of cyclosporin A versus azathioprine. Ann N Y Acad Sci 1987; 505: 872-875
  • 67 Arsura EL. Experience with intravenous immunoglobulin in myasthenia gravis. Clin Immunol Immunopathol 1989; 53 (2 Pt 2) S170-S179
  • 68 Wolfe GI, Barohn RJ, Foster BM , et al; Myasthenia Gravis-IVIG Study Group. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002; 26 (4) 549-552
  • 69 Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007; 68 (11) 837-841
  • 70 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41 (6) 789-796
  • 71 Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76 (23) 2017-2023
  • 72 Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis 2011; 13 (2) 85-94
  • 73 Pinching AJ, Peters DK, Newsom-Davis J. Remission of myasthenia gravis following plasma-exchange. Lancet 1976; 2 (8000) 1373-1376
  • 74 Behan PO, Shakir RA, Simpson JA, Burnett AK, Allan TL, Haase G. Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. Lancet 1979; 2 (8140) 438-440
  • 75 Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011; 76 (3) 294-300
  • 76 Mandawat A, Mandawat A, Kaminski HJ, Shaker ZA, Alawi AA, Alshekhlee A. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve 2011; 43 (4) 578-584
  • 77 Seybold ME. Plasmapheresis in myasthenia gravis. Ann N Y Acad Sci 1987; 505: 584-587
  • 78 Perez MC, Buot WL, Mercado-Danguilan C, Bagabaldo ZG, Renales LD. Stable remissions in myasthenia gravis. Neurology 1981; 31 (1) 32-37
  • 79 De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002; 26 (1) 31-36
  • 80 Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: “rebooting” with high-dose cyclophosphamide. Ann Neurol 2003; 53 (1) 29-34
  • 81 Evoli A, Di Schino C, Marsili F, Punzi C. Successful treatment of myasthenia gravis with tacrolimus. Muscle Nerve 2002; 25 (1) 111-114
  • 82 Kawaguchi N, Yoshiyama Y, Nemoto Y, Munakata S, Fukutake T, Hattori T. Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr Med Res Opin 2004; 20 (8) 1269-1273
  • 83 Konishi T, Yoshiyama Y, Takamori M, Yagi K, Mukai E, Saida T. Japanese FK506 MG Study Group. Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve 2003; 28 (5) 570-574
  • 84 Ponseti JM, Azem J, Fort JM, Codina A, Montoro JB, Armengol M. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin Neurol Neurosurg 2005; 107 (3) 187-190
  • 85 Minami N, Fujiki N, Doi S , et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 2011; 300 (1–2) 59-62
  • 86 Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus. Intern Med 2008; 47 (8) 731-736
  • 87 Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis—a randomized pilot study. Eur Neurol 2005; 53 (3) 146-150
  • 88 Ponseti JM, Gamez J, Azem J, López-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci 2008; 1132: 254-263
  • 89 Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82 (9) 970-977
  • 90 Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55 (7) 1062-1063
  • 91 Gajra A, Vajpayee N, Grethlein SJ. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004; 77 (2) 196-197
  • 92 Wylam ME, Anderson PM, Kuntz NL, Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003; 143 (5) 674-677
  • 93 Nelson Jr RP, Pascuzzi RM, Kessler K , et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis 2009; 10 (4) 170-177
  • 94 Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011; 4 (5) 259-266
  • 95 Blum S, Gillis D, Brown H , et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82 (6) 659-663
  • 96 Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006; 33 (4) 575-580
  • 97 Díaz-Manera J, Martínez-Hernández E, Querol L , et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78 (3) 189-193
  • 98 Rowin J, Meriggioli MN, Tüzün E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 2004; 63 (12) 2390-2392
  • 99 Tüzün E, Meriggioli MN, Rowin J, Yang H, Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment. J Autoimmun 2005; 24 (3) 261-268
  • 100 Fee DB, Kasarskis EJ. Myasthenia gravis associated with etanercept therapy. Muscle Nerve 2009; 39 (6) 866-870
  • 101 Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11: 97
  • 102 Soliven B, Rezania K, Gundogdu B, Harding-Clay B, Oger J, Arnason BG. Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci 2009; 277 (1-2) 150-154
  • 103 Soltys J, Kusner LL, Young A , et al. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 2009; 65 (1) 67-75